Quantitative Assessment of ^99mTc-Depreotide Uptake in Patients with Non-Small-Cell Lung Cancer: Immunohistochemical Correlations

References

• Cheng YL, Lee SC, Harn HJ, Chen CJ, Chang YC, Chen JC, et al. Prognostic prediction of the immunohistochemical expression of p53 and p16 in the resected non small cell lung cancer. Eur J Cardiothorac Surg 2003; 23: 221–8
   PubMed Web of Science ®Google Scholar
• Murakami I, Hiyama K, Ishioka S, Yamakido M, Kasagi F, Yokosaki Y. p53 gene mutations are associated with shortened survival in patients with advanced non small cell lung cancer: an analysis of medically managed patients. Clin Cancer Res 2000; 6: 526–30
   PubMed Web of Science ®Google Scholar
• Shiba M, Kohno H, Kakizawa K, Iizasa T, Otsuji M, Saitoh Y, et al. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected non small cell lung carcinoma. Cancer 2000; 89: 1457–65
   PubMed Web of Science ®Google Scholar
• Greatens TM, Niehans GA, Rubins JB, Jessurun J, Kratzke RA, Maddaus MA, et al. Do molecular markers predict survival in non-small-cell lung cancer?. Am J Respir Crit Care Med 1998; 157: 1093–7
   PubMed Web of Science ®Google Scholar
• Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52: 4828–31
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 2018–23
   PubMedGoogle Scholar
• Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995; 13: 1893–903
   PubMed Web of Science ®Google Scholar
• Passlick B, Izbicki JR, Häussinger K, Thetter O, Pantel K. Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J Thorac Cardiovasc Surg 1995; 109: 1205–11
   PubMed Web of Science ®Google Scholar
• Apolinario RM, van der Valk P, de Jong JS, Deville W, van Ark-Otte J, Dingemans AM, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997; 15: 2456–66
   PubMed Web of Science ®Google Scholar
• Pence JC, Kerns BJ, Dodge RK, Iglehart JD. Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg 1993; 128: 1382–90
   PubMedGoogle Scholar
• Nieder C, Andratschke N, Jeremic B, Molls M. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Res 2003; 23: 5117–23
   PubMed Web of Science ®Google Scholar
• Patz EF, Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE 2nd. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 2007; 25: 5578–83
   PubMed Web of Science ®Google Scholar
• Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, 2nd, Patz EF, Jr. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 2008; 26: 1459–64
   PubMed Web of Science ®Google Scholar
• Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg 2008; 33: 819–823
   PubMed Web of Science ®Google Scholar
• Bååth M, Kölbeck KG, Danielsson R. Somatostatin receptor scintigraphy with 99m-Tc-depreotide (NeoSpect) in discriminating between malignant and benign lesions in the diagnosis of lung cancer: a pilot study. Acta Radiol 2004; 45: 833–9
   PubMed Web of Science ®Google Scholar
• Naalsund, A, Maublant, J, on behalf of the European NeoSpect trial group. The solitary pulmonary nodule—is it malignant or benign? Diagnostic performance of 99m-Tc-depreotide SPECT. Respiration 2006;73:634–41.
   PubMed Web of Science ®Google Scholar
• Danielsson R, Bååth M, Svensson L, Forslöw U, Kölbeck KG. Imaging of regional lymph node metastases with 99m-Tc-depreotide in patients with lung cancer. Eur J Nucl Med Mol Imaging 2005; 32: 925–31
   PubMed Web of Science ®Google Scholar
• Kahn D, Menda Y, Kernstine K, Bushnell D, McLaughlin K, Miller S, et al. The utility of 99m Tc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. Chest 2004; 125: 494–501
   PubMed Web of Science ®Google Scholar
• Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, et al. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res 1998; 58: 1850–9
   PubMed Web of Science ®Google Scholar
• Axelsson R, Herlin G, Bååth M, Aspelin P, Kölbeck KG. Role of scintigraphy with technetium-99m depreotide in the diagnosis and management of patients with suspected lung cancer. Acta Radiol 2008; 49: 295–302
   PubMed Web of Science ®Google Scholar
• O'Byrne KJ, Carney DN. Somatostatin and the lung. Lung Cancer 1993; 10: 151–72
   PubMed Web of Science ®Google Scholar
• Fujita T, Yamaji Y, Sato M, Murao K, Takahara J. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2 in human lung cancer cell lines. Life Sci 1994; 55: 1797–806
   PubMed Web of Science ®Google Scholar
• O'Byrne KJ, Halmos G, Pinski J, Groot K, Szepeshazi K, Schally AV, et al. Somatostatin receptor expression in lung cancer. Eur J Cancer 1994; 30: 1682–7
   Web of Science ®Google Scholar
• Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. WHO classification of tumors: pathology and genetics of tumors of the lung, pleura, thymus and heart. IARC Press, Lyon 2004
   Google Scholar
• Kwekkeboom DJ, Kho GS, Lamberts SW, Reubi JC, Laissue JA, Krenning EP. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994; 21: 1106–13
   PubMedGoogle Scholar
• Machac J, Krynyckyi B, Kim C. Peptide and antibody imaging in lung cancer. Semin Nucl Med 2002; 32: 276–92
   PubMed Web of Science ®Google Scholar
• Shih WJ, Samayoa L. Tc-99m depreotide detecting malignant pulmonary nodules: histopathologic correlation with semi-quantitative tumor-to-normal lung ratio. Clin Nucl Med 2004; 29: 171–6
   PubMed Web of Science ®Google Scholar